Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, May 31 '25)

Image
By G.M.


 

    Am J Respir Crit Care Med

  1. KRISHNAN JA, Cao B, Chotirmall SH, Ely EW, et al
    Using the 2024 NASEM Definition of Long COVID: Implications for Pulmonary and Critical Care Medicine.
    Am J Respir Crit Care Med. 2025.
    PubMed        


    BMJ

  2. IBRAHIM S, Siemieniuk RAC, Oliveros MJ, Islam N, et al
    Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis.
    BMJ. 2025;389:e081165.
    PubMed         Abstract available

  3. BOSAEED M, Alraddadi BM
    Navigating the complexities of mild and moderate covid-19 treatment.
    BMJ. 2025;389:r1016.
    PubMed        

  4. TANNE JH
    US no longer recommends covid-19 vaccinations for pregnant women or children.
    BMJ. 2025;389:r1104.
    PubMed        

  5. O'DOWD A, Iacobucci G
    Covid-19: Early call to test healthcare staff was ignored, inquiry hears.
    BMJ. 2025;389:r1092.
    PubMed        


    Clin Infect Dis

  6. WOLFE CR, Cohen J, Mahoney K, Holmes A, et al
    Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY).
    Clin Infect Dis. 2025 May 24:ciaf265. doi: 10.1093.
    PubMed         Abstract available


    Emerg Infect Dis

  7. ROSAS IO, Benitez A, McKinnell JA, Shah R, et al
    Long-Term Clinical Outcomes of Adults Hospitalized for COVID-19 Pneumonia.
    Emerg Infect Dis. 2025;31:1158-1168.
    PubMed         Abstract available


    Int J Infect Dis

  8. DEBIE Y, Verbruggen L, Peeters M, van Dam PA, et al
    mRNA COVID-19 vaccines induce superior IgA titers in cancer patients compared to viral vector vaccines: Implications for immunization strategies.
    Int J Infect Dis. 2025 May 23:107939. doi: 10.1016/j.ijid.2025.107939.
    PubMed         Abstract available


    J Infect

  9. RIEDMANN U, Chalupka A, Richter L, Werber D, et al
    Corrigendum to "Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: A cohort study" [J Infect 90 (2025) 106497].
    J Infect. 2025;91:106522.
    PubMed        


    J Med Virol

  10. PIAZZESE C, Williams S, Brentall A, Kele B, et al
    Analysis of Variants' Dynamic Using the CLIMB Database in COVID-19 Patients Admitted to Hospitals of Barts Health NHS Trust.
    J Med Virol. 2025;97:e70402.
    PubMed         Abstract available

  11. LIU K, Rao J, Hu X, Sun H, et al
    Maternal Vaccination and Protective Immunity Against SARS-CoV-2 Infection in Pups.
    J Med Virol. 2025;97:e70418.
    PubMed         Abstract available

  12. PENG W, Wei X, Wu Y, Shi C, et al
    Dynamic Molecular Changes in Brain, Lung, and Heart of Hamsters Infected With SARS-CoV-2: Insights From a Severe and Recovery Phase Model.
    J Med Virol. 2025;97:e70410.
    PubMed         Abstract available

  13. ALIYARI SR, Shanaa J, Yu D, Yamamoto M, et al
    Suppression of Monkeypox Virus by Downregulation of Fatty Acid Synthase and Upregulation of Cholesterol-25 Hydroxylase.
    J Med Virol. 2025;97:e70403.
    PubMed         Abstract available


    J Virol

  14. WANG Y, Tong W, Qin W, Yang X, et al
    Midnolin inhibits coronavirus proliferation by degrading viral proteins.
    J Virol. 2025 May 29:e0036625. doi: 10.1128/jvi.00366.
    PubMed         Abstract available

  15. GUO L, Duan X, Li J, Hao Z, et al
    YIPF5 is an essential host factor for porcine epidemic diarrhea virus double-membrane vesicle formation.
    J Virol. 2025 May 27:e0032025. doi: 10.1128/jvi.00320.
    PubMed         Abstract available

  16. POGANY J, Inaba J-i, Liu Y, Nagy PD, et al
    Screening bacterial effectors and human virus proteins in yeast to identify host factors driving tombusvirus RNA recombination: a role for autophagy and membrane phospholipid content.
    J Virol. 2025 May 27:e0166124. doi: 10.1128/jvi.01661.
    PubMed         Abstract available


    Lancet Infect Dis

  17. FOLEGATTI PM, Pepin S, Tabar C, Fries K, et al
    Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study.
    Lancet Infect Dis. 2025 May 21:S1473-3099(25)00153.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  18. LAMBROU AS, South E, Midgley CM, Harrington C, et al
    Update on the Epidemiology of Middle East Respiratory Syndrome Coronavirus - Worldwide, 2017-2023.
    MMWR Morb Mortal Wkly Rep. 2025;74:313-320.
    PubMed         Abstract available


    Nature

  19. HILL R, Yin Y, Stein C, Wang X, et al
    The pivot penalty in research.
    Nature. 2025 May 28. doi: 10.1038/s41586-025-09048.
    PubMed         Abstract available

  20. ZHAO Y, Zheng B, Saunois M, Ciais P, et al
    Air pollution modulates trends and variability of the global methane budget.
    Nature. 2025 May 28. doi: 10.1038/s41586-025-09004.
    PubMed         Abstract available


    Radiologia (Engl Ed)

  21. PEREZ LAENCINA M, Plasencia Martinez JM, Sanchez Canales M, Jimenez Pulido C, et al
    A commercial AI tool untrained for COVID-19 demonstrates slight improvement in the interpretation of COVID-19 pneumonia x-rays, especially among inexperienced readers.
    Radiologia (Engl Ed). 2025;67:273-286.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »